These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10676629)

  • 1. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate.
    Henderson BW; Busch TM; Vaughan LA; Frawley NP; Babich D; Sosa TA; Zollo JD; Dee AS; Cooper MT; Bellnier DA; Greco WR; Oseroff AR
    Cancer Res; 2000 Feb; 60(3):525-9. PubMed ID: 10676629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen.
    Busch TM; Wileyto EP; Emanuele MJ; Del Piero F; Marconato L; Glatstein E; Koch CJ
    Cancer Res; 2002 Dec; 62(24):7273-9. PubMed ID: 12499269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.
    Sitnik TM; Henderson BW
    Photochem Photobiol; 1998 Apr; 67(4):462-6. PubMed ID: 9559590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model.
    Engbrecht BW; Menon C; Kachur AV; Hahn SM; Fraker DL
    Cancer Res; 1999 Sep; 59(17):4334-42. PubMed ID: 10485481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photofrin-mediated photodynamic therapy for treatment of aggressive head and neck nonmelanomatous skin tumors in elderly patients.
    Gayl Schweitzer V
    Laryngoscope; 2001 Jun; 111(6):1091-8. PubMed ID: 11404627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictions of mathematical models of tissue oxygenation and generation of singlet oxygen during photodynamic therapy.
    Yuan J; Mahama-Relue PA; Fournier RL; Hampton JA
    Radiat Res; 1997 Oct; 148(4):386-94. PubMed ID: 9339955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluence rate as a modulator of PDT mechanisms.
    Henderson BW; Busch TM; Snyder JW
    Lasers Surg Med; 2006 Jun; 38(5):489-93. PubMed ID: 16615136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photodynamic therapy for the treatment of basal cell carcinoma.
    Wilson BD; Mang TS; Stoll H; Jones C; Cooper M; Dougherty TJ
    Arch Dermatol; 1992 Dec; 128(12):1597-601. PubMed ID: 1456752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Photofrin photobleaching for singlet oxygen dose estimation during photodynamic therapy of MLL cells in vitro.
    Dysart JS; Patterson MS
    Phys Med Biol; 2005 Jun; 50(11):2597-616. PubMed ID: 15901957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome.
    Ericson MB; Sandberg C; Stenquist B; Gudmundson F; Karlsson M; Ros AM; Rosén A; Larkö O; Wennberg AM; Rosdahl I
    Br J Dermatol; 2004 Dec; 151(6):1204-12. PubMed ID: 15606516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of photosensitizer dose on fluence rate responses to photodynamic therapy.
    Wang HW; Rickter E; Yuan M; Wileyto EP; Glatstein E; Yodh A; Busch TM
    Photochem Photobiol; 2007; 83(5):1040-8. PubMed ID: 17880498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Photodynamic therapy for gastric cancer].
    Mimura S; Narahara H; Uehara H; Otani T; Okuda S
    Gan To Kagaku Ryoho; 1996 Jan; 23(1):41-6. PubMed ID: 8546468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome.
    Itkin A; Gilchrest BA
    Dermatol Surg; 2004 Jul; 30(7):1054-61. PubMed ID: 15209801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative clinical trial of photodynamic therapy with photofrin II and excimer dye laser for early gastric cancer.
    Mimura S; Ito Y; Nagayo T; Ichii M; Kato H; Sakai H; Goto K; Noguchi Y; Tanimura H; Nagai Y; Suzuki S; Hiki Y; Hayata Y
    Lasers Surg Med; 1996; 19(2):168-72. PubMed ID: 8887919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of laser photodynamic therapy on tumor phosphate levels and pH assessed by 31P-NMR spectroscopy.
    Gibson SL; Ceckler TL; Bryant TG; Hilf R
    Cancer Biochem Biophys; 1989 Oct; 10(4):319-28. PubMed ID: 2533522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome.
    Wang HW; Putt ME; Emanuele MJ; Shin DB; Glatstein E; Yodh AG; Busch TM
    Cancer Res; 2004 Oct; 64(20):7553-61. PubMed ID: 15492282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choice of optimal wavelength for PDT: the significance of oxygen depletion.
    Nielsen KP; Juzeniene A; Juzenas P; Stamnes K; Stamnes JJ; Moan J
    Photochem Photobiol; 2005; 81(5):1190-4. PubMed ID: 15934793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequencing of combined hyperthermia and photodynamic therapy.
    Chen Q; Chen H; Shapiro H; Hetzel FW
    Radiat Res; 1996 Sep; 146(3):293-7. PubMed ID: 8752307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of various photoradiation regimens on the antitumor efficacy of photodynamic therapy for R3230AC mammary carcinomas.
    Gibson SL; VanDerMeid KR; Murant RS; Raubertas RF; Hilf R
    Cancer Res; 1990 Nov; 50(22):7236-41. PubMed ID: 2171760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor effect of PDT using Photofrin in a mouse angiosarcoma model.
    Jin I; Yuji M; Yoshinori N; Makoto K; Mikio M
    Arch Dermatol Res; 2008 Apr; 300(4):161-6. PubMed ID: 18080130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.